About Orexigen Therapeutics (NASDAQ:OREX)
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:OREX
CUSIP68616410
Phone858-875-8600
Debt
Debt-to-Equity Ratio-2.75%
Current Ratio2.00%
Quick Ratio1.71%
Price-To-Earnings
Trailing P/E Ratio-0.03
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$33.71 million
Price / Sales0.12
Cash FlowN/A
Price / CashN/A
Book Value$3.91 per share
Price / Book0.06
Profitability
EPS (Most Recent Fiscal Year)($6.92)
Net Income$-24,520,000.00
Net Margins-192.65%
Return on EquityN/A
Return on Assets-68.53%
Miscellaneous
Employees132
Outstanding Shares18,890,000
Orexigen Therapeutics (NASDAQ:OREX) Frequently Asked Questions
What is Orexigen Therapeutics' stock symbol?
Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."
How were Orexigen Therapeutics' earnings last quarter?
Orexigen Therapeutics, Inc. (NASDAQ:OREX) issued its quarterly earnings data on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($2.13) by $0.78. The biopharmaceutical company earned $18.90 million during the quarter, compared to the consensus estimate of $24.20 million. The company's revenue for the quarter was up 170.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.12 EPS. View Orexigen Therapeutics' Earnings History.
Are investors shorting Orexigen Therapeutics?
Orexigen Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totalling 741,785 shares, a decline of 34.7% from the February 28th total of 1,135,890 shares. Based on an average daily trading volume, of 1,925,083 shares, the days-to-cover ratio is currently 0.4 days. Currently, 4.3% of the company's shares are short sold.
Who are some of Orexigen Therapeutics' key competitors?
Some companies that are related to Orexigen Therapeutics include Anthera Pharmaceuticals (ANTH), SenesTech (SNES), Epistem (GDR), InspireMD (NSPR), Heat Biologics (HTBX), OXiGENE (MATN), Bioblast Pharma (ORPN), Apricus Biosciences (APRI), Amedica (AMDA), STRATA Skin Sciences (SSKN), Avinger (AVGR), Cotinga Pharmaceuticals (COTQF), TearLab (TEAR), Rosetta Genomics (ROSG), Lombard Medical Technologies (EVARF), Affymax (AFFY), TetraLogic (TLOG) and BG Medicine (BGMD).
Who are Orexigen Therapeutics' key executives?
Orexigen Therapeutics' management team includes the folowing people:
- Mr. Michael A. Narachi, Pres, Chief Exec. Officer & Director (Age 59)
- Dr. Thomas R. Cannell D.V.M., Exec. VP, COO & Pres of Global Commercial Products (Age 56)
- Mr. Thomas P. Lynch, Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. (Age 51)
- Ms. Monica Forbes, VP & Acting CFO (Age 42)
- Mr. Stephen A. Moglia, Chief Accounting Officer, VP and Controller (Age 53)
Has Orexigen Therapeutics been receiving favorable news coverage?
Media stories about OREX stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Orexigen Therapeutics earned a media sentiment score of 0.10 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.31 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Orexigen Therapeutics?
Shares of OREX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Orexigen Therapeutics' stock price today?
One share of OREX stock can currently be purchased for approximately $0.2229.
How big of a company is Orexigen Therapeutics?
Orexigen Therapeutics has a market capitalization of $4.21 million and generates $33.71 million in revenue each year. The biopharmaceutical company earns $-24,520,000.00 in net income (profit) each year or ($6.92) on an earnings per share basis. Orexigen Therapeutics employs 132 workers across the globe.
How can I contact Orexigen Therapeutics?
Orexigen Therapeutics' mailing address is 3344 N. TORREY PINES CT. SUITE 200, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-875-8600 or via email at [email protected]
MarketBeat Community Rating for Orexigen Therapeutics (OREX)
MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe OREX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OREX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Orexigen Therapeutics (NASDAQ:OREX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Orexigen Therapeutics in the last 12 months. There are currently 1 sell rating for the stock, resulting in a consensus rating of "Sell."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Sell | Sell | N/A | N/A |
| Consensus Rating Score: | 1.00 | 1.00 | N/A | N/A |
| Ratings Breakdown: | 1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Orexigen Therapeutics (NASDAQ:OREX) Consensus Price Target History
Orexigen Therapeutics (NASDAQ:OREX) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/13/2018 | Wells Fargo | Downgrade | Underperform | | High |  |
(Data available from 4/21/2016 forward)
Orexigen Therapeutics (NASDAQ:OREX) Earnings History and Estimates Chart
Orexigen Therapeutics (NASDAQ OREX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | Q3 2017 | ($2.13) | ($1.35) | $24.20 million | $18.90 million | View | N/A | |
| 8/8/2017 | Q2 2017 | ($2.40) | ($1.82) | $20.00 million | $23.36 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($2.60) | ($4.67) | $20.00 million | $19.10 million | View | Listen | |
| 3/28/2017 | Q4 2016 | ($0.54) | ($2.67) | | $13.88 million | View | N/A | |
| 11/3/2016 | Q316 | ($2.24) | $1.12 | $8.17 million | $7.00 million | View | N/A | |
| 8/4/2016 | Q216 | ($1.47) | ($1.73) | $6.88 million | $7.79 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.17) | ($0.15) | $7.78 million | $5.00 million | View | Listen | |
| 2/26/2016 | Q415 | ($0.08) | ($0.12) | $14.07 million | $4.90 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.16) | ($0.09) | $12.17 million | $10.00 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.17) | ($0.18) | $4.92 million | $5.20 million | View | Listen | |
| 5/8/2015 | Q115 | ($0.16) | ($0.14) | $7.28 million | $4.36 million | View | Listen | |
| 11/10/2014 | Q3 | ($0.13) | $0.09 | $8.93 million | $30.90 million | View | Listen | |
| 8/7/2014 | Q2 | ($0.21) | ($0.21) | $51.80 million | $0.86 million | View | Listen | |
| 5/8/2014 | Q1 | ($0.20) | ($0.23) | $0.93 million | $0.86 million | View | Listen | |
| 3/12/2014 | Q4 | ($0.19) | ($0.21) | $900.00 million | $857.00 million | View | Listen | |
| 11/12/2013 | Q3 | ($0.18) | ($0.19) | $0.80 million | $0.8570 million | View | Listen | |
| 8/6/2013 | Q2 2013 | ($0.19) | ($0.19) | $0.90 million | $0.86 million | View | Listen | |
| 5/8/2013 | Q1 2013 | ($3.40) | ($2.10) | $0.92 million | $0.86 million | View | N/A | |
| 3/13/2013 | Q4 2012 | ($0.44) | ($0.41) | $0.91 million | $0.8570 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.30) | ($0.44) | | | View | N/A | |
| 8/7/2012 | Q2 2012 | ($1.70) | ($2.46) | | | View | N/A | |
| 5/9/2012 | Q1 2012 | ($1.20) | ($1.58) | | | View | N/A | |
| 3/8/2012 | Q4 2011 | ($1.00) | ($0.88) | | | View | N/A | |
| 11/8/2011 | Q3 2011 | ($1.40) | ($0.95) | | | View | N/A | |
| 8/8/2011 | Q2 2011 | ($2.00) | ($1.60) | | | View | N/A | |
| 5/9/2011 | Q1 2011 | ($2.10) | ($2.42) | | | View | N/A | |
| 3/10/2011 | Q4 2010 | ($2.90) | ($2.37) | | | View | N/A | |
| 11/3/2010 | Q3 2010 | ($2.70) | ($3.09) | | | View | N/A | |
| 8/5/2010 | Q2 2010 | ($3.20) | ($2.52) | | | View | N/A | |
| 5/10/2010 | Q1 2010 | ($3.00) | ($2.98) | | | View | N/A | |
| 3/9/2010 | Q4 2009 | ($2.80) | ($3.19) | | | View | N/A | |
| 11/4/2009 | Q3 2009 | ($3.60) | ($3.30) | | | View | N/A | |
| 8/6/2009 | Q2 2009 | ($5.60) | ($5.14) | | | View | N/A | |
| 5/7/2009 | Q1 2009 | ($5.80) | ($5.58) | | | View | N/A | |
| 3/12/2009 | Q4 2008 | ($7.20) | ($6.43) | | | View | N/A | |
| 11/6/2008 | Q3 2008 | ($6.50) | ($7.21) | | | View | N/A | |
| 8/7/2008 | Q2 2008 | ($6.60) | ($6.74) | | | View | N/A | |
| 5/8/2008 | Q1 2008 | ($6.10) | ($7.27) | | | View | N/A | |
| 3/13/2008 | Q4 2007 | ($6.70) | ($7.21) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Orexigen Therapeutics (NASDAQ:OREX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Orexigen Therapeutics (NASDAQ OREX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 36.43%
Orexigen Therapeutics (NASDAQ OREX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/15/2018 | Stephen A Moglia | VP | Sell | 1,694 | $0.24 | $406.56 | | |
| 12/19/2016 | Stephen A. Moglia | VP | Sell | 800 | $1.96 | $1,568.00 | | |
| 12/2/2014 | Heather D Turner | SVP | Sell | 22,643 | $6.00 | $135,858.00 | | |
| 11/25/2014 | Heather D Turner | SVP | Sell | 31,388 | $5.83 | $182,992.04 | | |
| 11/18/2014 | Louis C Bock | Director | Buy | 1,325 | $5.58 | $7,393.50 | | |
| 11/12/2014 | Louis C Bock | Director | Buy | 27,052 | $5.57 | $150,679.64 | | |
| 9/22/2014 | Heather D Turner | VP | Sell | 300,000 | $4.47 | $1,341,000.00 | | |
| 9/15/2014 | Joseph P Hagan | VP | Buy | 5,000 | $4.69 | $23,450.00 | | |
| 9/15/2014 | Michael Narachi | CEO | Buy | 50,000 | $4.78 | $239,000.00 | | |
| 7/31/2013 | Joseph P Hagan | Insider | Sell | 12,000 | $7.80 | $93,600.00 | | |
| 7/26/2013 | Joseph P Hagan | Insider | Sell | 10,000 | $7.40 | $74,000.00 | | |
| 7/25/2013 | Preston Klassen | SVP | Sell | 71,229 | $7.16 | $509,999.64 | | |
| 5/28/2013 | Joseph P Hagan | Insider | Sell | 28,000 | $7.00 | $196,000.00 | | |
| 5/28/2013 | Preston Klassen | SVP | Sell | 28,771 | $7.21 | $207,438.91 | | |
| 1/15/2013 | Mark D Booth | Insider | Sell | 22,315 | $6.67 | $148,841.05 | | |
(Data available from 1/1/2013 forward)
Orexigen Therapeutics (NASDAQ OREX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Orexigen Therapeutics (OREX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 19 at 2:24 PM |
![[$$] Orexigen Incentive, Retention Plans Opposed by Unsecured Creditors](/images/news-sites/YahooFinance.jpg "[$$] Orexigen Incentive, Retention Plans Opposed by Unsecured Creditors") | [$$] Orexigen Incentive, Retention Plans Opposed by Unsecured Creditors
finance.yahoo.com - April 11 at 4:07 PM |
| Orexigen Therapeutics, Inc. (OREX) Short Interest Down 34.7% in March
www.americanbankingnews.com - March 31 at 1:45 AM |
| [$$] Firm Retention Summary: Orexigen Therapeutics Inc.
finance.yahoo.com - March 28 at 10:00 AM |
| Should You Buy Orexigen Therapeutics Inc (NASDAQ:OREX) At $0.22?
finance.yahoo.com - March 23 at 9:30 AM |
| 30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets
finance.yahoo.com - March 22 at 4:22 PM |
 | Orexigen Files For Bankruptcy - Investors Need To Get Savvy - Seeking Alpha
seekingalpha.com - March 19 at 4:14 PM |
| Orexigen Therapeutics (OREX) Downgraded by Wells Fargo to Underperform
www.americanbankingnews.com - March 18 at 11:25 AM |
| Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code
finance.yahoo.com - March 14 at 12:40 PM |
| [$$] Orexigen to Use Some Bankruptcy Financing on Advertising
finance.yahoo.com - March 14 at 12:40 PM |
| Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy
finance.yahoo.com - March 14 at 12:40 PM |
 | Orexigen, Advaxis Tumble into Tuesday's 52-Week Low Club - 24/7 Wall St.
247wallst.com - March 13 at 4:22 PM |
 | Obesity drug developer Orexigen in bankruptcy to pursue sale - Reuters
www.reuters.com - March 13 at 4:22 PM |
 | Orexigen Therapeutics (OREX) to File Chapter 11 Bankruptcy
www.streetinsider.com - March 13 at 11:35 AM |
| US STOCKS-Wall Street set to open higher as inflation worries ease
finance.yahoo.com - March 13 at 11:35 AM |
| Orexigen Bankruptcy Shows Difficulty of Marketing Weight-Loss Drugs
finance.yahoo.com - March 13 at 11:35 AM |
 | Mid-Day Market Update: Dow Turns Negative; United Community Bancorp Shares Spike Higher - Nasdaq
www.nasdaq.com - March 12 at 4:03 PM |
| Mid-Afternoon Market Update: BlueLinx Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge - Nasdaq
www.nasdaq.com - March 12 at 4:03 PM |
| BRIEF-Orexigen Therapeutics says plans near-term sale through Chapter 11 of US bankruptcy code - Reuters
www.reuters.com - March 12 at 5:19 AM |
| [$$] Orexigen Plans to Sell Itself Through Chapter 11 Bankruptcy
finance.yahoo.com - March 12 at 5:19 AM |
 | Orexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy Code
www.prnewswire.com - March 12 at 2:26 AM |
| Orexigen Therapeutics, Inc. (OREX) Expected to Post Earnings of -$2.06 Per Share
www.americanbankingnews.com - March 4 at 1:32 PM |
| Sangamo Therapeutics Announces Appointment Of Heather D. Turner As Senior Vice President And General Counsel - PR Newswire (press release)
www.prnewswire.com - February 13 at 6:13 AM |
 | Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its ... - Business Wire (press release)
www.businesswire.com - February 9 at 3:27 PM |
| Orexigen Therapeutics (OREX) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 6:36 PM |
| Global Anti-Obesity Drugs Market 2017-2023: Market is Estimated to Witness a CAGR of 20.9% - Key Players are F. Hoffmann La Roche, GSK, Orexigen Therapeutics, Vivus Therapeutics, and Eisai
www.prnewswire.com - February 1 at 8:06 AM |
| -$2.06 Earnings Per Share Expected for Orexigen Therapeutics, Inc. (OREX) This Quarter
www.americanbankingnews.com - January 29 at 9:14 PM |
| Why Orexigen Therapeutics Inc’s (NASDAQ:OREX) Ownership Structure Is Important
finance.yahoo.com - January 24 at 8:50 AM |
| BRIEF-Orexigen Therapeutics Says Expect Annualized Savings Associated With Feb 2018 Reduction In Sales Force Of About $30 Mln
www.reuters.com - January 19 at 11:45 AM |
| Orexigen Therapeutics (OREX) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 16 at 11:54 AM |
 | Orexigen Struggles as Contrave Commercialization Costs Rise
www.zacks.com - January 4 at 4:38 PM |
| Orexigen Therapeutics (OREX) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - January 4 at 6:04 AM |
| ETFs with exposure to Orexigen Therapeutics, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 1:54 PM |
| Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 27 at 1:54 PM |
| Zacks: Brokerages Expect Orexigen Therapeutics, Inc. (OREX) Will Announce Earnings of -$2.06 Per Share
www.americanbankingnews.com - December 27 at 12:33 PM |
| Comparing Orexigen Therapeutics (OREX) and MacroGenics (MGNX)
www.americanbankingnews.com - December 11 at 9:52 PM |
| Implied Volatility Surging for Orexigen (OREX) Stock Options
finance.yahoo.com - December 8 at 10:16 AM |
| Is Orexigen Therapeutics Inc (OREX) An Industry Laggard Or Leader?
finance.yahoo.com - December 1 at 5:35 PM |
| Ophthotech (OPHT) vs. Orexigen Therapeutics (OREX) Head to Head Analysis
www.americanbankingnews.com - November 28 at 5:38 AM |
| Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt ... - PR Newswire (press release)
www.prnewswire.com - November 15 at 7:11 AM |
| Earnings Reaction History: Orexigen Therapeutics, Inc., 62.5% Follow-Through Indicator, 7.7% Sensitive - Nasdaq
www.nasdaq.com - November 15 at 7:11 AM |
| Orexigen Therapeutics Announces Third Quarter 2017 Financial ... - PR Newswire (press release)
www.prnewswire.com - November 15 at 7:11 AM |
| What Does Orexigen Therapeutics Inc’s (OREX) Share Price Indicate?
finance.yahoo.com - November 15 at 7:11 AM |
| Orexigen Therapeutics, Inc. (OREX) Announces Quarterly Earnings Results, Beats Expectations By $0.78 EPS
www.americanbankingnews.com - November 14 at 10:30 AM |
| BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt
www.reuters.com - November 14 at 6:35 AM |
| Orexigen Therapeutics' (OREX) CEO Michael Narachi on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 14 at 6:35 AM |
| Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin America
finance.yahoo.com - November 14 at 6:35 AM |
| Orexigen Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 6:34 AM |
| Orexigen reports 3Q loss
finance.yahoo.com - November 14 at 6:34 AM |
| Edited Transcript of OREX earnings conference call or presentation 13-Nov-17 10:00pm GMT
finance.yahoo.com - November 14 at 6:34 AM |
Orexigen Therapeutics (NASDAQ:OREX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Orexigen Therapeutics (NASDAQ:OREX) Income Statement, Balance Sheet and Cash Flow Statement
Orexigen Therapeutics (NASDAQ OREX) Stock Chart for Saturday, April, 21, 2018
Loading chart…
